| Literature DB >> 35277035 |
Teresa Trotta1, Chiara Porro1, Antonia Cianciulli2, Maria Antonietta Panaro2.
Abstract
Spirulina is a microscopic, filamentous cyanobacterium that grows in alkaline water bodies. It is extensively utilized as a nutraceutical food supplement all over the world due to its high levels of functional compounds, such as phycocyanins, phenols and polysaccharides, with anti-inflammatory, antioxidant, immunomodulating properties both in vivo and in vitro. Several scientific publications have suggested its positive effects in various pathologies such as cardiovascular diseases, hypercholesterolemia, hyperglycemia, obesity, hypertension, tumors and inflammatory diseases. Lately, different studies have demonstrated the neuroprotective role of Spirulina on the development of the neural system, senility and a number of pathological conditions, including neurological and neurodegenerative diseases. This review focuses on the role of Spirulina in the brain, highlighting how it exerts its beneficial anti-inflammatory and antioxidant effects, acting on glial cell activation, and in the prevention and/or progression of neurodegenerative diseases, in particular Parkinson's disease, Alzheimer's disease and Multiple Sclerosis; due to these properties, Spirulina could be considered a potential natural drug.Entities:
Keywords: Alzheimer’s disease; Parkinson’s disease; astrocytes; microglia; multiple sclerosis; neurodegeneration diseases; neuroinflammation; phycocyanin; spirulina
Mesh:
Substances:
Year: 2022 PMID: 35277035 PMCID: PMC8839264 DOI: 10.3390/nu14030676
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Role of Spirulina in glial cells. Spirulina exerts anti-inflammatory activity with consequent neuronal damage and the onset of neuroinflammatory and/or neurodegenerative disorders, reducing (↓) glial cell activation and proinflammatory molecules, and up-regulating (↑) superoxide dismutase (SOD) and neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF).
Summary of in-vivo experimental evidence suggesting that Spirulina or its components cross the BBB.
| Component/Route of Administration | Animal Model | Summary of Results | Ref. |
|---|---|---|---|
| Spirulina/Orally | Adult male Sprague–Dawley rats with cerebral ischemia | Reduction of infarction area in the cerebral cortex | [ |
| Increase in locomotor activity | |||
| Decline in TUNEL positive cells and caspase-3 activity | |||
| Spirulina/Orally | Protein malnourished Sprague Dawley female rats | Increased cerebral cortical thickness | [ |
| Reduction in oxidative brain damage | |||
| Reduction in astrocyte and microglia activation | |||
| PCB/Intraperitoneally | Male Wistar rats with cerebral ischemia | Reduction in the area of cerebral infarction | [ |
| Normalized expression of myelin basic protein and enzyme CNPase | |||
| Preserved vitality of cerebral cortex neurons | |||
| Spirulina maxima 70% ethanol extract (SM70EE)/Orally | Male ICR mice treated with scopolamine | Reduction in learning and memory deficits | [ |
| C-PC/Intraperitoneally | Male Wistar rats treated with tributyltin chloride (TBTC) | Increased C-PC bioavailability in cerebral cortical tissue | [ |
| Reduction in astrocyte and microglia activation | |||
| Reduction in oxidative stress and inflammation | |||
| C-PC/Orally | Male Sprague Dawley rats treated with kainic acid | Reduction in microglia and astroglia activation | [ |
| Reduced incidence of neurobehavioral changes | |||
| Spirulina/Orally | Male SW mice treated with kainic acid | Reduction of neuron damage in CA3 hippocampal region | [ |
| Spirulina/Orally | Male Fisher 344 rats treated with α-Syn in substantia nigra | Reduction in the number of activated microglial cell | [ |
| Increased expression of the fractalkine receptor (CX3CR1) on microglia | |||
| Spirulina/Orally | Male Wistar rats treated with 6-OHDA | Reduction in oxidative stress | [ |
| Preserved dopamine levels in the striatum | |||
| Normalized locomotor activity | |||
| Spirulina/Orally | male C-57 black mice treated with MPTP | Partial reduction of dopamine content in the striatum | [ |
| Reduction in oxidative stress | |||
| Polysaccharide from Spirulina/Intraperitoneally | C57BL/6J mice treated with MPTP | Increased mRNA expression of dopamine transporter and tyrosine hydroxylase | [ |
| Increased SOD and GPx activity | |||
| Spirulina maxima 70% ethanol extract (SM70EE)/Orally | Male ICR mice treated with Aβ1–42 | Reduced oxidative stress | [ |
| Increased GSH, GPx1 and GR levels in the hippocampus | |||
| PCB/Intraperitoneally | Male Wistar rats subjected to permanent bilateral occlusion of the common carotid arteries | Modulated 190 genes associated to immunological and inflammatory processes | [ |
| Phycocyanin/Intraperitoneally | Female Wistar rats treated with Streptozotocin | Reduction in neuroinflammation | [ |
| Improved levels of BDNF, IGF-1, BCL-2 and ChAT | |||
| Improved gene expression of IRS-1, PI3-K, AKT | |||
| C-PC/Orally | Lewis rats with EAE | Restoration of motor function | [ |
| Reduced oxidative damage | |||
| Preserved the integrity of myelin sheaths | |||
| PCB/Orally | C57BL/6 mice with EAE | [ | |
| Improved clinical status of animals | |||
| Reduction in IL-6 and IFN-γ expression in the brain | |||
| C-PC/Orally or Intraperitoneally | Male Mongolian gerbils with global cerebral ischemia | Reduction in infarct volume | [ |
| Decreased neuronal damage | |||
| Reduction in malondialdehyde (MDA), peroxidation potential (PP) and FRAP levels | |||
| S. platensis-LPS (S.LPS)/Intraperitoneally | Male albino Wistar rats treated with nicotine | Enhancement in antioxidant enzymes’ activities | [ |
| Improved level of TNF-α, IL-17 and NF-κB in brain tissues | |||
| Prevention of Tau protein phosphorylation |
Figure 2Effects of Spirulina in neurodegenerative diseases.